Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.
Advertisement

Related Content

Cymbalta's Expanded GAD Claim Is A Load Off Lilly's Mind
Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor
Cymbalta Fibromyalgia sNDA Could Make Lilly Product Lyrica’s First Competitor
Pfizer’s Lyrica Is First Drug Approved For Fibromyalgia
Pfizer’s Lyrica Is First Drug Approved For Fibromyalgia
AstraZeneca’s Seroquel Gets FDA Nod For Bipolar Depression
Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review
Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review

Topics

Advertisement
UsernamePublicRestriction

Register

PS065682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel